NCT07136805View on ClinicalTrials.gov

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Non-infectious Anterior Uveitis
Interventions
DRUG

VVN461 Ophthalmic Solution 1.0%

1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

DRUG

1.0% prednisolone acetate

1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

All Listed Sponsors
lead

VivaVision Biotech, Inc

INDUSTRY